anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a four-arm randomized, controlled trial with a 24-week intervention period and 12-week follow-up period. Participants are considered ready to be randomized once they have completed all surveys, established a baseline step count, and selected a step goal increase.Participants in the control arm will receive no other interventions during the 24-week intervention period or the 12-week follow-up period. Participants randomized to the one of the three intervention arms will have a 4-week ramp up towards their step goal. The participant will then be asked to maintain their goal during the 20-week "maintenance period" and the 12-week "follow-up period." Participants in arms 2-4 will be entered into an intervention approach that has points and levels designed to incorporate insights from behavioral economics. Participants in the supportive social incentive arm will be asked to identify a family member or friend to be their support sponsor. This sponsor will be encouraged to support the participant in their progress during the study. Participants in the competitive social incentive arm will be in a group of three total participants.At the end of each week the participants will receive notification that ranks them on their cumulative points in the study thus far and also displays their level.This feedback may help to induce participants to compete for the top spot among the group. Participants in the collaborative social incentive arm will be in a group of three total participants as a team. Each day one of the members of the group will be randomly selected to represent their team for that day. In this design, each person is accountable to the others on the team and this may induce a collaborative effort to meet their daily goals.
Solid dry stable preparations of calcium or magnesium acetylsalicylate are manufactured by intimately incorporating therewith a minor amount (e.g. 2-3 per cent) of calcium or magnesium chloride and a minor amount (e.g. 0.25-0.4 per cent) of calcium or magnesium carbonate.  The process may be effected, in the case of calcium acetylsalicylate, by adding, with even admixture, to a filtered concentrated aqueous solution of an alkali metal (e.g. sodium) salt of acetylsalicylic acid, a small quantity of an alkali metal (e.g. sodium) carbonate, precipitating the product with excess of calcium chloride, filtering, extracting liquid until the product retains the desired amount of calcium chloride, and drying, advantageously at 45-50 DEG  C.  Preparations of magnesium acetylsalicylate may be obtained similarly by replacing the alkali metal salt of acetylsalicylic acid by magnesium acetylsalicylate, the alkali metal carbonate by a carbonate of magnesium (preferably the basic carbonate), and the calcium chloride by magnesium chloride. Examples of both these procedures are given.
BACKGROUND: Chronic diseases have a high prevalence worldwide, and patients with chronic diseases often suffer from depression, leading to a poor prognosis and a low quality of life. Metacognitive therapy is a transdiagnostic psychotherapy intervention focused on thinking patterns, with the advantages of reliable implementation effect, short intervention period and low cost. It can help patients change negative metacognition, alleviate depression symptoms, and has a higher implementation value compared with other cognitive interventions. Therefore, metacognitive therapy may be an effective way to improve the mental health of patients with chronic diseases.
METHODS AND ANALYSIS: CNKI, Wanfang Database, VIP Database for Chinese Technical Periodicals, Sinomed, PubMed, SCOPUS, Embase, The Cochrane Library, Web of Science and PsycINFO will be used to select the eligible studies. As a supplement, websites (eg, the Chinese Clinical Registry, ClinicalTrials.gov) will be searched and grey literature will be included. The heterogeneity and methodological quality of the eligible studies will be independently screened and extracted by two experienced reviewers. All the data synthesis and analysis (drawing forest plots, subgroup analysis and sensitive analysis) will be conducted using RevMan 5.4.1.
ETHICS AND DISSEMINATION: This article is a literature review that does not include patients' identifiable information. Therefore, ethical approval is not required in this protocol. The findings of this systematic review and meta-analysis will be published in a peer-reviewed journal as well as presentations at relevant conferences.
PROSPERO REGISTRATION NUMBER: CRD42023411105.
A compsn. for treating the hair contains an alpha-ketodicarboxylic acid or physiologically acceptable salt. Pref. the acid is alpha-ketoglutaric acid or a salt, in amt. of 0.1-10 wt.%, and the compsn. has pH 2-7, and is a soln., enulsion, cream, gel, powder or aerosol foam. It may also contain anionic, cationic, amphoteric, zwitterionic or nonionic surfactants, foam synergists or stabilisers, sequestrants, emulsifiers, natural substances, pigments, perfume oils, opacifiers, pearl gloss agents, etc. USE/ADVANTAGE - Use of alpha-ketodicarboxylic acids or salts to remove residues of H2O2 from the hair is claimed. Residual H2O2 damages and bleaches the hair and affects later dyeing. The compsn. is effective at alkaline and acid pH, physiologically acceptable, and stable.
Provided is an extracellular domain of a mammalian Fat1 (Fat1 EC ). Also provided is an intracellular domain of a mammalian Fat1 (Fat1 IC ). Additionally provided is a vector comprising a nucleic acid sequence encoding the Fat1 EC . A vector comprising a nucleic acid sequence encoding the Fat1 IC  is further provided. Also, a vascular stent coated with the Fat1 EC  is provided. Further provided is a vascular stent coated with a Fat1 ligand that activates Fat1. A method of treating a patient at risk for restenosis of a blood vessel is additionally provided. Further, methods of treating an injured blood vessel in a patient is provided. A method of treating a patient at risk for restenosis of a blood vessel or having an injured blood vessel is also provided.
BACKGROUND: Patients undergoing immediate breast reconstruction with tissue expanders are frequently admitted after surgery for monitoring and pain control, which introduces additional costs and risks of nosocomial infection. Same-day discharge could conserve resources, mitigate risk, and return patients home for faster recovery. The authors used large data sets to investigate the safety of same-day discharge after mastectomy with immediate postoperative expander placement.
METHODS: A retrospective review was performed of patients in the National Surgical Quality Improvement Program database who underwent breast reconstruction using tissue expanders between 2005 and 2019. Patients were grouped based on date of discharge. Demographic information, medical comorbidities, and outcomes were recorded. Statistical analysis was performed to determine efficacy of same-day discharge and identify factors that predict safety.
RESULTS: Of the 14,387 included patients, 10% were discharged the same day, 70% on postoperative day 1, and 20% later than postoperative day 1. The most common complications were infection, reoperation, and readmission, which trended upward with length of stay (6.4% versus 9.3% versus 16.8%), but were statistically equivalent between same-day and next-day discharge. The complication rate for later-day discharge was statistically higher. Patients discharged later had significantly more comorbidities than same or next-day discharge counterparts. Predictors of complications included hypertension, smoking, diabetes, and obesity.
CONCLUSIONS: Patients undergoing mastectomy with immediate tissue expander reconstruction are usually admitted overnight. However, same-day discharge was demonstrated to have an equivalent risk of perioperative complications as next-day discharge. For the otherwise healthy patient, going home the day of surgery is a safe and cost-effective option, although the decision should be made based on the individual patient.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
Frameworks conceptualising the quality of care abound and vary; some concentrate on specific aspects such as safety, effectiveness, others all-encompassing. However, to our knowledge, tailoring to systematically arrive at a comprehensive care for chronic conditions quality (CCCQ) framework has never been done. We conducted a scoping review and Delphi survey to produce a CCCQ framework, comprehensively delineating aims, determinants and measurable attributes. With the assumption that specific groups (people with chronic conditions, care providers, financiers, policy-makers, etc.) view quality of care differently, we analysed 48 scientific and 26 grey literature deductively and inductively using the Institute of Medicine's quality of care framework as the foundation. We produced a zero-version of the quality of chronic care framework, detailing aims, healthcare system determinants, and measurement mechanisms. This was presented in a Delphi survey to 49 experts with diverse chronic care expertise/experience around the world. Consensus was obtained after the first round, with the panel providing suggestions and justifications to expand the agreed-upon components. Through this exercise, a comprehensive CCCQ framework encompassing the journey through healthcare of people with chronic conditions was developed. The framework specifies seven CCCQ 'aims' and identifies health system determinants which can be acted upon with 'organising principles' and measured through chronic care quality 'attributes' related to structures, processes and outcomes. Tailoring quality of care based on the nature of the diseases/conditions and considering different views can be done to ensure a comprehensive offer of healthcare services, and towards better outcomes that are acceptable to both the health system and people with chronic conditions (PwCC).
Bronchiectasis involves the irreversible dilation and damage of the bronchi, forming an important long-term sequela in patients who have completed treatment for lung tuberculosis. This condition leads to restricted chest expansion, severe shortness of breath, and chronic cough, causing considerable distress to the affected patients' quality of life. Pulmonary rehabilitation, through aerobic exercise and breathing techniques such as Pursed Lip Breathing (PLB) and the Active Cycle of Breathing Technique (ACBT), has shown benefits in managing these symptoms. The potential additional benefit of exercises involving accessory respiratory muscles to improve chest wall mobility, using Respiratory Muscle Stretching (RMS) exercises, has not been well-explored. This single-blind randomized controlled trial will compare the effects of standard pulmonary rehabilitation alone versus standard rehabilitation combined with RMS exercises in patients with bronchiectasis post-tuberculosis. Outcomes will focus on changes in chest expansion, dyspnea, cough symptoms, and lung function parameters such as FEV1, FVC, and FEV1/FVC ratio. The study will involve 48 participants who meet the inclusion criteria and will run for four weeks.
The invention discloses a method for inducing human adipose-derived stem cells to differentiate into chondrocytes in vitro and application thereof, and relates to the technical field of biology. The method comprises the following steps of S1: isolated culturing human adipose-derived stem cells in vitro, wherein the human adipose-derived stem cells are cultured in a human adipose-derived stem cell culture solution; s2: inoculating the human adipose-derived stem cell culture solution in the step S1 into a cartilage induced differentiation medium, and inducing the human adipose-derived stem cells to differentiate into cartilage cells; the cartilage induced differentiation medium comprises the following components: basicm 98mL, dexamethasone 10. Mu.L, ascorbicac 300. Mu.L, insulin-transferin-Selenium maddrive 1mL, sodium Pyruvate 100. Mu.L, proline 100. Mu.L were prepared as 99.51mL premix with the above amounts, and TGF-. Beta.310. Mu.L/1 mL was additionally added before use. The method for inducing the human adipose-derived stem cells to differentiate into the chondrocytes in vitro has the advantages of strong specificity, good repeatability and high yield, and provides a theoretical basis and a guiding scheme for treating Osteoarthritis (OA) by the cells.
Infants are more sensitive to the side effects of general anesthesia than older children. This may be associated with the incomplete maturation of organ systems effective in pharmacodynamics. Regional anesthesia applications provide safe and effective analgesia by reducing the need for opioids. Regional anesthesia applications in infants require experience and complication rates due to central blocks are high. However, in recent years, the use of ultrasound (USG) has increased the use of safe and effective trunk blocks. There are studies on the use of Transversus Abdominis Plan Block (TAPB) and Quadratus Lumborum Block (QLB) in children. However, there is no comparative study on its use in infants.

In our study, we aimed to compare the effects of TAPB and QLB on postoperative pain score and analgesic consumption in infants who underwent unilateral inguinal hernia surgery.
PURPOSE: Cytokines regulate the interaction between the immune system and malignant tumors. Among them, interleukin-10 (IL-10) is a multifunctional anti-inflammatory cytokine mainly produced by immune cells. The correlation between gastric cancer and T/C single nucleotide polymorphism (SNP) of interleukin-10 (IL-10) promoter-819(rs1800871)was opaque and remained to be determined. We aim to explore the pertinence of gastric cancer and SNP of interleukin 10-819 by meta-analysis via five statistical models.
METHODS: Databases including PubMed, Cochrane Library, Embase, the Scopus, and Google Scholars were comprehensively retrieved for the eligible studies on the related topic from inception to March 2022. Odds ratios (ORs) were generated for dichotomous variants by meta-analysis in each model via STATA 17.0 MP. The statistical models comprised recessive model, over-dominant model, allele model, co-dominant model and dominant model. Subgroup analysis was performed to investigate the difference across races as well as the source of heterogeneity if necessary.
RESULTS: Eventually a total of 15 articles reporting 7779 patients were enrolled in our study. There were 2383 patients and 5396 controls, collectively. There was no correlation between gastric cancer and IL-10 819 in recessive model, co-dominant model or dominant model, and subgroup analysis showed that Asian, Latin American and Caucasian had no correlation with the risk of gastric cancer. In the allelic model, there was significant correlation between gastric cancer and IL-10 819 (OR = 3.96%, 95%CI: 3.28 to 3.78). In the over-dominant model, there is no correlation between gastric cancer and IL-10 819, but subgroup analysis uncovered significant vulnerability of Asian people with regard to gastric cancer.
CONCLUSIONS: In our study, both Asians, Latin Americans, and Europeans showed an increased risk of gastric cancer in the allelic model, whereas only Asians showed significant susceptibility in the super dominant model. Of course, more large cohort studies are needed to confirm our results.
Study CCG-1962

The safety and effectiveness of ONCASPAR was evaluated in an open label, multicenter, randomized, active controlled study (Study CCG-1962). In this study, 118 pediatric patients aged 1 to 9 years with previously untreated standard-risk ALL were randomized 1:1 to ONCASPAR or native E. coli L-asparaginase as part of combination therapy. ONCASPAR was administered intramuscularly at a dose of 2,500 International Units/m2 on Day 3 of the 4 week induction phase and on Day 3 of each of two 8 week delayed intensification phases. Native E. coli L-asparaginase was administered intramuscularly at a dose of 6,000 International Units/m2 three times weekly for 9 doses during induction and for 6 doses during each delayed intensification phase.

The primary determination of effectiveness was based on demonstration of similar asparagine depletion (magnitude and duration) in the ONCASPAR and native E. coli L-asparaginase arms. The protocol-specified goal was achievement of asparagine depletion to a serum concentration of ≤1 µM. The proportion of patients with this level of depletion was similar between the 2 study arms during all 3 phases of treatment at the protocol-specified time points.

In all phases of treatment, serum asparagine concentrations decreased within 4 days of the first dose of asparaginase in the treatment phase and remained low for approximately 3 weeks for both ONCASPAR and native E. coli L-asparaginase arms. Serum asparagine concentrations during the induction phase are shown in Figure 1. The patterns of serum asparagine depletion in the 2 delayed intensification phases are similar to the pattern of serum asparagine depletion in the induction phase.

Note: ONCASPAR (2,500 International Units/m2 intramuscular) was administered on Day 3 of the 4-week induction phase. Native E. coli L-asparaginase (6,000 International Units/m2 intramuscular) was administered 3 times weekly for 9 doses during induction.

CSF asparagine concentrations were determined in 50 patients during the induction phase. CSF asparagine decreased from a mean pre-treatment concentration of 3.1 µM to 1.7 µM on Day 4±1 and 1.5 µM at 25±1 days after administration of ONCASPAR. These findings were similar to those observed in the native E. coli L-asparaginase treatment arm.

Concentrations of asparaginase activities greater than 0.1 International Units/mL were observed in over 90% of the samples from patients treated with ONCASPAR during Induction, Delayed Intensification 1, and Delayed Intensification 2 for approximately 20 days.

While the 3-year Event-Free Survival (EFS) for the ONCASPAR and native E. coli L-asparaginase study arms were similar and in the range of 80%, Study CCG-1962 was not designed to evaluate for differences in EFS rates.
BACKGROUND: Gender-affirming top surgery is becoming increasingly common, with greater diversity in the patients receiving top surgery. The purpose of this study was to examine national trends in patient demographics, characteristics, wound complication rates, and concurrent procedures in patients receiving gender-affirming top surgeries.
METHODS: Patients with gender dysphoria who underwent breast procedures, including mastectomy, mastopexy, breast augmentation, or breast reduction by a plastic surgeon between 2013 and 2022, were identified from the American College of Surgeons National Surgical Quality Improvement Program database. These procedures were considered to be gender-affirming "top surgery." Univariate analyses were performed to examine trend changes in the patient population and types of additional procedures performed over the last decade.
RESULTS: There was a 38-fold increase in the number of patients who received top surgery during the most recent years compared to the first 2 years of the decade. Significantly more individuals receiving top surgery in recent years were nonbinary ( P < 0.01). There was a significant decrease in percentage of active smokers ( P < 0.01) while there was an increase in percentage of patients with diabetes ( P = 0.03). While there was a significant increase in the number of obese patients receiving top surgery ( P < 0.01), there were no differences in postoperative wound complications between the years. Significantly more patients received additional procedures ( P < 0.01) and had about a 9-fold increase in distinct number of additional CPT codes from 2013-2014 to 2021-2022.
CONCLUSIONS: Our study found that there has been (1) a significant increase in the number of top surgery patients from 2013 to 2022 overall and (2) a particular increase in patients with preoperative comorbidities, such as a higher body mass index and diabetes. Understanding current and evolving trends in patients undergoing surgical treatment for gender dysphoria can inform individualized care plans that best serve the needs of patients and optimize overall outcomes.
Pharmacodynamic studies have shown that acamprosate calcium reduces alcohol intake in alcohol- dependent animals in a dose-dependent manner and that this effect appears to be specific to alcohol and the mechanisms of alcohol dependence.

Acamprosate calcium has negligible observable central nervous system (CNS) activity in animals outside of its effects on alcohol dependence, exhibiting no anticonvulsant, antidepressant, or anxiolytic activity.

The administration of acamprosate calcium is not associated with the development of tolerance or dependence in animal studies. Acamprosate calcium did not produce any evidence of withdrawal symptoms in patients in clinical trials at therapeutic doses. Post marketing data, collected retrospectively outside the U.S. have provided no evidence of acamprosate calcium abuse or dependence.

Acamprosate calcium is not known to cause alcohol aversion and does not cause a disulfiram-like reaction as a result of ethanol ingestion.
The invention discloses a traditional Chinese medicine preparation for treating anal pointed condyloma. The preparation is prepared from the following raw materials by weight: 25-35g of gallnuts, 8-12g of smoked plums, 8-12g of rhizoma cyperi, 8-12g of peach kernels, 1.8-2.2g of realgar and 8-12g of dried alum. The preparation method comprises the following steps: mixing, crushing and sieving the raw material medicines by a 100-mesh screen; and adding vinegar to prepare an ointment. The traditional Chinese medicine preparation for treating anal pointed condyloma mainly treats anal pointed condyloma. The use of the preparation comprises the following steps: smearing the traditional Chinese medicine preparation at the affected parts, wherein the smearing area is appropriately 1cm greater than the wart area; and then covering by an adhesive plaster. Large warts shall be excised by an electrotome or laser, and the smearing area after excision is appropriately 1cm greater than the wound area. The preparation is smeared once every two days, the wart is remarkably reduced after smearing for three times commonly, and the wart commonly fall after smearing for seven times, so that the effect of cure is realized.
Synbiotics are complex preparations of prebiotics that can be selectively utilized by live microorganisms to improve host health. Synbiotics are divided into complementary synbiotics, which consist of probiotics and prebiotics with independent functions, and synergistic synbiotics, which consist of prebiotics that are selectively used by gut microorganisms. Complementary synbiotics used in human clinical trials include Lactobacillus spp. and Bifidobacterium spp. as probiotics, and fructooligosaccharides, galactooligosaccharides, and inulin as prebiotics. Over the past five years, synbiotics have been most commonly used in patients with metabolic disorders, including obesity, and immune and gastrointestinal disorders. Several studies have observed alterations in the microbial community; however, these changes did not lead to significant improvements in disease outcomes or biochemical and hematological markers. The same synbiotics have been applied to individuals with different gut environments. As a result, even with the same synbiotics, there are non-responders who do not respond to the applied synbiotics due to the different intestinal environment for each individual. Therefore, to obtain meaningful results, applying different synbiotics depending on the individual is necessary. Synergistic synbiotics are one solution to circumvent this problem, as they combine elements that can effectively improve health, even in non-responders. This review aims to explain the concept of synbiotics, highlight recent human clinical trials, and explore the current state of research on synergistic synbiotics.